PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New Products and Increased Patient Awareness Propel the U.S. Overactive Bladder Treatment Market Finds Frost & Sullivan - The U.S. overactive bladder (OAB) therapeutics market witnesses strong growth fuelled by the increase in diagnosed patient population, the rollout of new products, and increased awareness of this condition
New Products and Increased Patient Awareness Propel the U.S. Overactive Bladder Treatment Market Finds Frost & Sullivan

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2010/06/04 - The U.S. overactive bladder (OAB) therapeutics market witnesses strong growth fuelled by the increase in diagnosed patient population, the rollout of new products, and increased awareness of this condition.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The risk for OAB is greatest in Americans that are 65 and older. The population in this age bracket expects to increase by 20.9 percent, from 38.7 million in 2008 to 46.8 million in 2015. Additionally, the U.S. Census Bureau reports the fastest growing segment of the population to be aged 85 and above.

New analysis from Frost & Sullivan (pharma.frost.com), Overactive Bladder Market, finds the market earned revenues of over $1.6 billion in 2008, and estimates this to reach $2.94 billion in 2015. The study covers Detrol, Detrol LA, Ditropan, Ditropan XL, Enablex, Oytrol, Sanctura, Sanctura XR, VESIcare, and other emerging therapies.

If you are interested in more information on this study, please send an email to Johanna Haynes, Corporate Communications, at johanna.haynes[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.

"Currently, all of the FDA approved medications for the treatment of OAB are in the same class of drugs, and patients who cannot take these drugs are excluded from all medicinal options," says Frost & Sullivan Research Analyst Katheryn Symank. "Innovative therapies that are in a new class and address unmet needs have the potential to expand the OAB treatment market."

One new product, Mirabegron, utilizes a novel therapeutic approach making it. the first in a new class of medications for the treatment of OAB. This product will soon be available in the U.S. market in 2012.

Regardless of the fact that it is highly prevalent, OAB remains an underdiagnosed disorder. Patients with OAB wrongly assume treatment options are not available, or that OAB is a normal part of the aging process. As a result, large portions of those having this condition opt to suffer in silence.

Another issue contributing to the relatively low diagnosis rate for OAB is the lack of screening for this condition. The highly undiagnosed rate for OAB could hinder market development, and may impede its growth.

Although OAB is a relatively new term, there are several treatment options available. Many patients diagnosed with OAB are elderly and take multiple medications, causing concern about the risk of adverse effects from potential drug-drug interactions; therefore, most physicians do not initially use medications to treat this condition. The patient is advised to first try other treatments like physical therapy, behavioral therapy, or lifestyle modifications. Prescription medications are only used as a last resort.

Many physicians try to minimize the number of prescriptions for geriatric patients, keeping those with the highest critical return on investment (ROI) for the patient. Factors that define OAB medications as second-line therapies are marginal effectiveness and the lack of studies that compare drugs to other types of therapies. Going forward, efforts must intensify to spread awareness on the effective treatment options available for OAB.

"The availability of some popular commercials for medications that treat OAB has helped raise the awareness quotient with regard to this disorder," says Symank. "Not only do these advertisements bring this embarrassing condition to the mainstream, but they also help destigmatize it."

U.S. Overactive Bladder Market is part of the Pharmaceutical & Biotechnology Growth Partnership Services program, which also includes research in the following markets: U.S. Injectable Drug Pipeline and Global Vaccines Market. All research services included in the subscriptions provide detailed market opportunities and industry trends that were evaluated after extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.

U.S. Overactive Bladder Market / N695

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


New Products and Increased Patient Awareness Propel the U.S. Overactive Bladder Treatment Market Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Johanna Haynes 
210.247.3870 johanna.haynes[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
The Float Space - Brisbane's First Float and Cryo Therapy Centre to Open This November
Thought Leaders Across the Healthcare Spectrum to Participate in Industry-Wide Survey
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Moriarty Physical Therapy of the Hudson Valley Expands with New Office in Lagrange, NY
Ultimate Medical Group Announces A New Regenerative Medicine Division
Dr. Amir Hanna Introduces New Medical Innovation Taking the Pain Out of Physical Therapy
Samitivej Children’s Hospital Transforms its Sukhumvit Campus

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)